Projects

Edible flowers for ASD 

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairment in social interaction and communication, associated with repetitive and/or restricted behaviors and interests. The pathophysiology of ASD has not yet been fully elucidated, but it is known that the interaction of environmental and genetic factors influences it. Treatment is also not delimited and, therefore, new therapeutic alternatives have gained space, especially the brain-intestine axis, as it has been discovered that the gastrointestinal tract plays an important role in the development of ASD.  The objective of the study is to investigate the effects of Tagetes erecta dry extract (rich in lutein) on neurobehavioral and intestinal changes in different animal models of ASD (valproic acid and NF1). To this end, experiments will be carried out on two models of autism, the valproic acid model (carried out in Brazil) and the NF1 neurofibromatosis model (carried out in Portugal), with the animals being treated from weaning until P60 with food-enriched with 0.3 % of Tageres erecta extract, when behavioral tests will be carried out, and subsequently sacrificed for tissue collection (serum, colon, ileum, cortex, hippocampus and cerebellum) and biochemical, immunohistochemical, intestinal permeability and serotonin dosage tests. Partial results point to effects on social interaction (females), anxiety-like behavior (males), and memory (females and males).

autism spectrum disorder | tagetes erecta | gut-brain axis

Joanna Sievers

2024

Plasticity recovery in neurodevelopmental disorders by cell-selective and systems-level GABAergic manipulation 

Neurodevelopmental disorders, including autism spectrum disorders (ASD) and schizophrenia, require effective treatments. Neural plasticity impairment is commonly associated with these diseases, leading to altered neural circuitry and excitation/inhibition (E/I) imbalances, resulting in suboptimal brain connectivity and behavioral issues. Current therapeutic approaches, such as pharmacological and brain stimulation therapies, have failed or shown poor outcomes due to a lack of circuit selectivity. Effective treatment must target specific neural circuits and cell types to restore impaired circuits and achieve lasting cognitive improvements. Our lab focuses on neurofibromatosis type 1 (NF1), characterized by E/I imbalances and GABA neurotransmitter changes. NF1 mice exhibit memory and learning deficits linked to increased inhibitory neurotransmission, particularly via PV fast-spiking interneurons. We hypothesize that inhibiting PV-neurons in NF1 will enhance plasticity, allowing input-specific synaptic connections to be strengthened and maintained. We propose combining PV-neuron inhibition with transcranial direct current stimulation (tDCS) to enhance its effectiveness.

We anticipate two major advances: identifying disease-related circuits to encourage targeted therapies in neurodevelopmental disorders and improving tDCS-based interventions. This approach may benefit a range of conditions with plasticity-related neuropsychiatric implications, such as ASD, schizophrenia, epilepsy, and depression.

visual system | neurofibromatosis type 1 | excitation-inhibition | brain stimulation

Amount 10 000€

2021